Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2012

View Archived Issues

Zebra fish: A promising model organism to study CNS disorders

Multiple novel CCR2 receptor antagonists synthesized at Janssen

Series A financing supports development of Novira antivirals

New models designed to predict drug toxicity for liver and kidney

French team designs novel antiangiogenic agents

Astellas Pharma patents new serotonin 5-HT5A receptor ligands

Novel candidate cancer drugs presented

New antimicrobial products isolated in India

Selective Na(V)1.7 channel inhibitor shows promise as an analgesic

MORAb-004 enters new phase II trial

FDA approves Exalgo sNDA

PARAMOUNT study reveals beneficial effects of LCZ-696

Recruitment begins for phase III trial in children with precocious puberty

Alder Biopharmaceuticals earns milestone payment for phase II study

New alpha2C-adrenoceptor agonists discovered at Merck & Co.

BioTime gains expanded license to HyStem technology

Neuralstem completes stem cell trial in ALS

TG Therapeutics highlights potential of ublituximab for new indication

FDA lifts clinical hold

Tenelia set for launch in Japan

FDA approves new combination pill for HIV

FDA places clinical hold on HCV NS5B inhibitor

NeutroPhase cleared for use in new indications

FDA provides recommendations for Proellex trial

Controlled-release tablets for PD launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.